Stock of the Day

December 23, 2022

Iovance Biotherapeutics (IOVA)

$8.12
-$0.06 (-0.7%)
Market Cap: $3.68B

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Trend

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is receiving mixed analyst signals, but the overall tone is modestly supportive as investors focus on the company’s oncology pipeline and improving long-term earnings expectations.

  • Price target raised: Iovance’s price target was increased to $10.00, implying continued upside from recent trading levels and providing a potential catalyst for the stock. Iovance Biotherapeutics Price Target Raised to $10.00
  • Some earnings revisions improved: Zacks Research raised its Iovance EPS forecasts for the third quarter of 2026, full-year 2026, second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2026 loss estimate improved from $0.62 to $0.56 per share, while the FY2028 loss estimate improved from $0.10 to $0.07, suggesting expectations for better profitability over time.
  • Sector interest: Iovance was highlighted among oncology companies benefiting from continued innovation in cancer treatments. The company’s focus on cell therapy could support investor interest in its commercial and pipeline opportunities. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
  • Forecasts remain mixed: Zacks lowered estimates for the first quarter of 2027, third and fourth quarters of 2027, full-year 2027 and first quarter of 2028, including a reduction in the FY2027 loss forecast from $0.36 to $0.44 per share. These cuts offset several of the improved estimates.
  • Profitability remains ahead, not immediate: Zacks still expects Iovance to report losses through the forecast period, including estimated losses of $0.56 per share in FY2026 and $0.44 in FY2027. Investors therefore remain dependent on revenue growth, commercial execution and clinical progress rather than near-term profits. Zacks Industry Outlook
← Previous Stock of the DayNext Stock of the Day →